Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SELLAS Life Sciences' value hinges on the pivotal REGAL phase 3 trial in AML, with interim results showing promise. Click ...

Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have ...

Step inside the Mercedes SLS AMG 6.3 Roadster for an immersive look at this iconic convertible supercar. From premium ...

Safran Landing Systems may not receive the same level of attention as other parts of the French aerospace group but with one ...

Weeks after the NC auditor’s report on spending for a shower and laundry care station for Swannanoa, the question of how and ...

Key Insights Solaris Resources' significant insider ownership suggests inherent interests in company's expansion ...

This video explores how Falcon Heavy, first launched in 2018, has outpaced NASA’s much-delayed and exorbitantly costly Space Launch System (SLS), which carries a price tag nearing $24 billion ...

Shares of fashion retailer Vishal Mega Mart (VMM) may draw attention this week as the lock-up period for over half its equity ...

Find out if Solaris Resources Inc Ordinary Shares (SLS:XTSE) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value ...

If signed into law as written, the White House's proposal to slash nearly 25 percent from NASA's budget would have some dire ...